EXEL Exelixis Inc.

19.72
-0.04  -0%
Previous Close 19.76
Open 19.9
Price To Book 3.73
Market Cap 5,991,849,154
Shares 303,846,306
Volume 2,868,557
Short Ratio
Av. Daily Volume 3,188,954
Stock charts supplied by TradingView

NewsSee all news

  1. Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

    – Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates – – Presentation and webcast at 2020 J.P.

  2. Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

    — Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

  3. Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

    – Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on

  4. Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

    – New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration

  5. Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis, Inc. (NASDAQ:EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 data due 1H 2020.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 interim analysis due 2H 2020.
Cabozantinib - COSMIC-311
Thyroid Carcinoma
Phase 3 trial met primary endpoint - December 13, 2019.`
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b data to be presented 11:30am PT, February 13, 2020 at ASCO GU.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 PFS and interim OS analysis due 2H 2020.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors
Phase 3 data due 2022.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Phase 4 PFS data due 2020.
Cabozantinib
Medullary Thyroid Cancer

Latest News

  1. Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance

    – Company announces anticipated timelines for data readouts from six cabozantinib potentially label-enabling clinical studies and up to three new potential IND candidates – – Presentation and webcast at 2020 J.P.

  2. Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

    — Presentation to be webcast on www.exelixis.com — Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

  3. Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors

    – Based on continued encouraging efficacy and safety data, metastatic castration-resistant prostate cancer cohort further expanded to 130 patients – – Initial data to be presented on

  4. Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors

    – New pivotal trials will evaluate the combination of cabozantinib and atezolizumab in patients with advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma – – Collaboration

  5. Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma

    Exelixis, Inc. (NASDAQ:EXEL) today announced positive results from IMspire150, the phase 3 trial of atezolizumab (TECENTRIQ®), cobimetinib (COTELLIC®) and vemurafenib (ZELBORAF®) in people with previously untreated BRAF

  6. Exelixis Announces Webcasts of Investor Conference Presentations in December

    – Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis' management team will provide an overview of the company at the following investor conferences

  7. Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview

  8. Exelixis' Partner Ipsen Announces Health Canada's Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma

    – Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen

  9. Exelixis' Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy

    -- Results being presented today in a late-breaking presentation (abstract TH-PO1201) at Kidney Week 2019, the annual meeting of the American Society of Nephrology in Washington, D.C. Exelixis, Inc. (NASDAQ:EXEL)

  10. Invenra Announces Expansion of Collaboration with Exelixis

    Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (NASDAQ:EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies

  11. Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    - Total Revenue of $271.7 Million, Cabozantinib Franchise Revenue of $191.8 Million - - GAAP Diluted EPS of $0.31, Non-GAAP Diluted EPS of $0.34 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis,

  12. Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of Exelixis management will provide a corporate overview at the 2019 Cantor Global Healthcare Conference,

  13. Exelixis to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019

    – Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview